Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment

Ahmad, Saeem; Khan, Iram; Pandit, Jayamanti; Emad, Nasr A.; Bano, Shahnaj; Dar, Khalid Imtiyaz; Rizvi, M Moshahid Alam; Ansari, Mohd Danish; Aqil, Mohd.; Sultana, Yasmin

doi:10.1016/j.ijbiomac.2022.08.210

Cited by 45 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the literature mainly described the cytotoxicity effect of the positively charged NPs in tumoral cells. 31 , 102 , 103 We observed a decrease in the percentage of cytotoxicity between the CCNPs and ChCNPs. It is probably due to the reduction of the positive surface charge.…”

Section: Resultsmentioning

confidence: 64%

“… 100 Moreover, the difference between the work of Albarki et al and previous studies could be due not only to the timescale of the experiments but also to the difference between cancerous and normal cells. 31 …”

Section: Resultsmentioning

confidence: 99%

“…The objective of this work is the development of dry chitosan-coated cubosomes and the comparison of their efficiency for N2B delivery with standard and cationic CNPs. Indeed, the literature describes many NPs coated with chitosan (e.g PLGA NPs, 31 , 32 liposomes, 20 , 33 nanostructured lipid carrier 34 ) but no cubosomes. Dry formulations were used because their efficacity to reach the brain, in comparison with liquid formulations, was extensively reported.…”

Section: Introductionmentioning

confidence: 99%

“…Indeed, the C max in the brain was 1.33 times higher for their PLGA-NPs coated with chitosan than for the drug suspension (5235.028 ± 5.00 and 3943.23 ± 5.77 ng/mL, respectively) after an intranasal administration in rats. 31 Thus, our work focused on developing a formulation using CNPs as an efficient carrier to encapsulate our lipophilic drug and chitosan to promote the permeation between the nasal epithelia. As described below, to cover the whole process of N2B delivery, we also used a nasal cast as a new tool for nasal in vitro assessment to map the pharmaceutic forms in the nasal cavities.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

In vitro Evaluation of Paliperidone Palmitate Loaded Cubosomes Effective for Nasal-to-Brain Delivery

Deruyver¹,

Rigaut²,

Gomez-Perez³

et al. 2023

IJN

View full text Add to dashboard Cite

Introduction This work aimed to develop chitosan-coated cubosomal nanoparticles intended for nose-to-brain delivery of paliperidone palmitate. They were compared with standard and cationic cubosomal nanoparticles. This comparison relies on numerous classical in vitro tests and powder deposition within a 3D-printed nasal cast. Methods Cubosomal nanoparticles were prepared by a Bottom-up method followed by a spray drying process. We evaluated their particle size, polydispersity index, zeta-potential, encapsulation efficiency, drug loading, mucoaffinity properties and morphology. The RPMI 2650 cell line was used to assess the cytotoxicity and cellular permeation. An in vitro deposition test within a nasal cast completed these measurements. Results The selected chitosan-coated cubosomal nanoparticles loaded with paliperidone palmitate had a size of 305.7 ± 22.54 nm, their polydispersity index was 0.166 ± 0.022 and their zeta potential was +42.4 ± 0.2 mV. This formulation had a drug loading of 70% and an encapsulation efficiency of 99.7 ± 0.1%. Its affinity with mucins was characterized by a ΔZP of 20.93 ± 0.31. Its apparent permeability coefficient thought the RPMI 2650 cell line was 3.00E-05 ± 0.24E-05 cm/s. After instillation in a 3D-printed nasal cast, the fraction of the injected powder deposited in the olfactory region reached 51.47 ± 9.30% in the right nostril and 41.20 ± 4.59% in the left nostril, respectively. Conclusion The chitosan coated cubosomal formulation seems to be the most promising formulation for nose-to-brain delivery. Indeed, it has a high mucoaffinity and a significantly higher apparent permeability coefficient than the two other formulations. Finally, it reaches well the olfactory region.

show abstract

Section: Resultsmentioning

confidence: 64%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

In vitro Evaluation of Paliperidone Palmitate Loaded Cubosomes Effective for Nasal-to-Brain Delivery

Deruyver¹,

Rigaut²,

Gomez-Perez³

et al. 2023

IJN

View full text Add to dashboard Cite

show abstract

“…Among synthetic polymers, poly(lactic-co-glycolic acid) (PLGA) copolymer has been widely investigated as a biocompatible and biodegradable material for the production of numerous drug delivery formulations, enabling encapsulation and controlled release of both hydrophobic and hydrophilic drugs [ 73 ]. Chitosan coating of PLGA-based nanoparticles has been mainly investigated to introduce muco-adhesive properties [ 55 , 56 ].…”

Section: Biomaterials-based Vehicles For In Drug Deliverymentioning

confidence: 99%

Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting

Marcello

Chiono

2023

IJMS

View full text Add to dashboard Cite

Intranasal (IN) drug delivery is a non-invasive and effective route for the administration of drugs to the brain at pharmacologically relevant concentrations, bypassing the blood–brain barrier (BBB) and minimizing adverse side effects. IN drug delivery can be particularly promising for the treatment of neurodegenerative diseases. The drug delivery mechanism involves the initial drug penetration through the nasal epithelial barrier, followed by drug diffusion in the perivascular or perineural spaces along the olfactory or trigeminal nerves, and final extracellular diffusion throughout the brain. A part of the drug may be lost by drainage through the lymphatic system, while a part may even enter the systemic circulation and reach the brain by crossing the BBB. Alternatively, drugs can be directly transported to the brain by axons of the olfactory nerve. To improve the effectiveness of drug delivery to the brain by the IN route, various types of nanocarriers and hydrogels and their combinations have been proposed. This review paper analyzes the main biomaterials-based strategies to enhance IN drug delivery to the brain, outlining unsolved challenges and proposing ways to address them.

show abstract

Neuroprotective and anti‐inflammatory effects of curcumin in Alzheimer's disease: Targeting neuroinflammation strategies

Azzini,

Peña‐Corona,

Hernández‐Parra

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid‐beta plaques and neurofibrillary tangles, leading to neuronal loss. Curcumin, a polyphenolic compound derived from Curcuma longa, has shown potential neuroprotective effects due to its anti‐inflammatory and antioxidant properties. This review aims to synthesize current preclinical data on the anti‐neuroinflammatory mechanisms of curcumin in the context of AD, addressing its pharmacokinetics, bioavailability, and potential as a therapeutic adjunct. An exhaustive literature search was conducted, focusing on recent studies within the last 10 years related to curcumin's impact on neuroinflammation and its neuroprotective role in AD. The review methodology included sourcing articles from specialized databases using specific medical subject headings terms to ensure precision and relevance. Curcumin demonstrates significant neuroprotective properties by modulating neuroinflammatory pathways, scavenging reactive oxygen species, and inhibiting the production of pro‐inflammatory cytokines. Despite its potential, challenges remain regarding its limited bioavailability and the scarcity of comprehensive human clinical trials. Curcumin emerges as a promising therapeutic adjunct in AD due to its multimodal neuroprotective benefits. However, further research is required to overcome challenges related to bioavailability and to establish effective dosing regimens in human subjects. Developing novel delivery systems and formulations may enhance curcumin's therapeutic potential in AD treatment.

show abstract

Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment

Cited by 45 publications

References 52 publications

In vitro Evaluation of Paliperidone Palmitate Loaded Cubosomes Effective for Nasal-to-Brain Delivery

In vitro Evaluation of Paliperidone Palmitate Loaded Cubosomes Effective for Nasal-to-Brain Delivery

Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting

Neuroprotective and anti‐inflammatory effects of curcumin in Alzheimer's disease: Targeting neuroinflammation strategies

Contact Info

Product

Resources

About